文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

抗体药物偶联物治疗期间孤立性中枢神经系统进展的局部治疗

Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy.
PubMed 文献 · Adv Radiat Oncol · 2025-01-13

本研究回顾性分析17例接受抗体药物偶联物(ADC)治疗期间出现孤立性脑进展并接受放疗的患者,其中立体定向放射外科13例、全脑放疗4例,全部同期继续ADC治疗。中位随访29.5个月,中位总生存19个月,中位无进展生存8.1个月,24个月局部失败累积发生率1.6%,6个月放射性坏死累积发生率为12%。作者认为局部治疗可能延迟需要下一线全身治疗的时间,尤其在寡进展性脑复发患者中。

要点

  • ADC治疗期间孤立性脑进展接受局部放疗并继续同线治疗,中位总生存19个月。
  • 24个月局部失败累积发生率为1.6%,6个月放射性坏死累积发生率为12%。
  • 6个月和12个月下一线治疗累积发生率分别为47%和71%,寡进展患者显著更低。

核心结论

  • 据作者所知,这是首份在ADC治疗患者中采用指南推荐的孤立性脑复发局部治疗策略的临床结局报告。
  • 局部治疗可能延迟需要下一线全身治疗的时间,尤其在寡进展性脑复发患者中。

研究设计与样本

  • 回顾性查询本机构数据库,纳入接受ADC治疗期间出现孤立性脑进展、接受放疗并计划放疗后继续同线治疗的患者17例。
  • 复发时脑转移灶≤3个的患者归类为寡进展。
  • 放疗方式为立体定向放射外科13例、全脑放疗4例,全部患者同期接受ADC与放疗。
  • 研究终点包括总生存、无进展生存及自局部治疗起下一线治疗的累积发生率。

主要发现

  • 自局部治疗起中位随访29.5个月(95%CI,21.4至未达到)。
  • 中位总生存19个月(95%CI,16至未达到),中位无进展生存8.1个月(范围,6.7-19个月)。
  • 1个接受立体定向放射外科治疗的病灶在治疗后21个月出现局部失败,整个队列24个月局部失败累积发生率为1.6%(95%CI,0.13%-7.7%)。
  • 6个月放射性坏死累积发生率为12%(95%CI,1.8%-32%)。
  • 6个月和12个月下一线治疗累积发生率分别为47%(95%CI,22%-69%)和71%(95%CI,41%-87%),在寡进展性脑复发患者中显著更低。

关键数值与推荐

  • 指南推荐对孤立性脑复发患者进行局部治疗并继续当前全身治疗。
  • 复发时脑转移灶≤3个归类为寡进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Antibody drug conjugates (ADCs) are an increasingly important class of therapeutics among patients with breast, lung, urothelial, and other malignancies. Guidelines recommend local therapy and continuation of current systemic therapy among patients with isolated brain relapse. We describe the clinical outcomes of this approach among patients receiving ADCs. METHODS AND MATERIALS: We queried our institutional database for patients receiving radiation therapy (RT) in the setting of isolated brain progression on ADCs with a plan to continue same-line therapy after radiation. Patients with ≤3 brain metastases at the time of recurrence were categorized as oligoprogressive. Study endpoints included overall survival, progression-free survival (PFS), and the cumulative incidence of next therapy from the start of local therapy. RESULTS: We identified 17 patients receiving ADC therapy with isolated brain progression treated with radiation (stereotactic radiosurgery [SRS]: n = 13, whole brain radiation: n = 4). All patients received concurrent ADC and RT. The median follow-up from local therapy was 29.5 months (95% CI, 21.4-not reached). The median overall survival was 19 months (95% CI, 16-not reached), and the median PFS was 8.1 months (range, 6.7-19 months). One lesion treated with SRS had local failure 21 months after treatment, and the 24-month cumulative incidence of local failure across the entire cohort was 1.6% (95% CI, 0.13%-7.7%). The 6-month cumulative incidence of radiation necrosis was 12% (95% CI, 1.8%-32%). The cumulative incidence of next therapy at 6 and 12 months was 47% (95% CI, 22%-69%) and 71% (95% CI, 41%-87%), respectively, and was significantly lower among patients with oligoprogressive brain recurrence. After SRS, 2 patients were without evidence of disease, discontinued systemic therapy, and were stable on observation at last follow-up. CONCLUSIONS: To the best of our knowledge, this is the first clinical report of outcomes using the guideline-recommended approach of local therapy for isolated brain relapse among patients receiving ADCs. Local therapy may delay the need for next line systemic therapy, particularly among patients with oligoprogressive brain relapse.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lebow ES, Eichholz J, Zhang Z, et al. Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy. Adv Radiat Oncol. 2025. PMID: 40092156. doi:10.1016/j.adro.2025.101714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。